2-Chloro-1-(3-hydroxyazetidin-1-yl)ethan-1-one is a heterocycle intermediate typically used in the preparation of Ziritaxestat (GLPG-1690), a selective autotaxin inhibitor for the treatment of patients with idiopathic pulmonary fibrosis (IPF) or chronic obstructive pulmonary diseases (COPD).
Catalyst-Free Cyclization- And Curtius Rearrangement-Induced Functional Group Transformation: An Improved Synthetic Strategy of First-in-Class ATX Inhibitor Ziritaxestat (GLPG-1690). 
 H.Lei, et al, Org. Process Res. Dev., 2020, 24(6), pp 997-1005.
NONH for all modes of transport
1. Product Specification
2. Safety Data Sheet
Please inquire for pricing and availability of this product by writing email firstname.lastname@example.org.